SARS-CoV-2 - Camostat mesylate - Therapeutic Candidates

SARS-CoV-2 - Camostat mesylate - Therapeutic Candidates


Camostat is a serine protease inhaler used, in the form of camostat mesilate, for the treatment of various pathologies such as certain cancers or fibrosis in kidney diseases.
CoV-2-CoRNA exploits the cell entry receptor protein, angiotensin II converting enzyme (ACE-2), to access and infect human cells. The interaction between ACE-2 and the lead protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat mesilate is a potent inhibitor of serine protease. Through research on the SARS-CoV-2 coronavirus and its closely related cell entry mechanism, it has been shown that the cellular entry of SARS-CoV-2 can be blocked by camostat mesilate. In mice, camostat mesilate administered at concentrations similar to the clinically achievable concentration in humans reduced mortality from SARS-CoV-2 infection from 100% to 30-35%. In addition, another study showed that camostat mesilate reduced SARS-CoV-2 infection of Calu-3 cells.

Cat#
Description
Size
Price Excl. VAT
M2487-100mg
 100 mg 
M2487-50mg
 50 mg 
S2391-100mg
 100mg 
S2391-25mg
 25mg 
S2391-50mg
 50mg 
B2082-100mg
 100 mg 
B2082-10mg
 10 mg 
B2082-50mg
 50 mg 
S2391-200mg
 200mg 
MBS575758-10mg
 10 mg 
MBS575758-25mg
 25 mg 
MBS575758-1ml
 1ml/10mM (In DMSO) 
MBS575758-50mg
 50 mg 
MBS575758-100mg
 100 mg